The excellent prognosis of the group of POLE-mutated tumors has been validated in numerous series of cases [2–11], and has led to incorporation of POLE mutation testing in tumor stratification in international guidelines, such as by ESGO-ESTRO-ESP [12] and FIGO [13]. The gene discussed is POLE; the disease is neoplasm.